3 highly rated ASX growth shares analysts love

Growth investors might want to take a closer look at these ASX shares…

| More on:
Surge in ASX share price represented by happy woman pointing to her big smile

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of growth shares for investors to choose from on the Australian share market.

To narrow things down, I have picked out three ASX growth shares that are highly rated. Here's what you need to know about them:

ELMO Software Ltd (ASX: ELO)

ELMO is a HR and payroll platform provider. It has been growing at an impressive rate over the last few years thanks to solid demand for its offering in the ANZ and UK markets and acquisitions. Positively, the company looks well-placed to continue this positive form thanks to the shift to the cloud, its significant addressable market, and cross- and up-selling opportunities.

One broker that is particularly positive on ELMO is Shaw & Partners. It currently has a buy rating and and $9.00 price target.

IDP Education Ltd (ASX: IEL)

IDP Education is a provider of international student placement and English language testing services. As you might expect, it was hit hard by the pandemic. However, thanks to its software business and strong balance sheet, the company has been tipped to win market share and resume its rapid growth once the crisis passes.

Morgan Stanley is positive on the company's post-pandemic prospects. As a result, it recently retained its overweight rating and $30.00 price target on the IDP Education's shares.

ResMed Inc. (ASX: RMD)

ResMed is a medical device company with a focus on the sleep treatment market. Thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed has been growing at a very strong rate over the last decade. Pleasingly, ResMed still has a significant market opportunity to grow into thanks to the growing prevalence of sleep disorders.

Credit Suisse is a fan of the company and believes upcoming launch of its new CPAP device, AirSense 11, will be a key driver of growth. The broker has an outperform rating and $29.00 price target on its shares.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Elmo Software and Idp Education Pty Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia owns shares of and has recommended Elmo Software. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Growth Shares

3 monster stocks to hold for the next 3 years

These 3 ASX shares operate in different industries and could be worth holding for long-term growth over the next 3…

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »